Send to printer »

GEN News Highlights : Dec 13, 2006

Vion Inks Manufacturing Deal for Anticancer Agent

Ben Venue will produce the Cloretazine currently in Phase III trials.

Ben Venue Laboratories will manufacture Vion Pharmaceuticals’ Cloretazine, its lead anticancer agent, under a manufacturing agreement. 

Cloretazine, an alkylating agent, is being evaluated in a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia (AML) and a Phase II trial in elderly patients with previously untreated de novo poor-risk AML.